Hong Kong Study Reveals Comparable Safety Profiles Between CoronaVac and BNT162b2 COVID-19 Vaccines

A comprehensive territory-wide cohort study in Hong Kong has provided crucial comparative safety data between two major COVID-19 (search)Search disease vaccine platforms, revealing reassuringly low rates of serious adverse events for both the inactivated CoronaVacView drug details vaccine and the mRNA BNT162b2View drug details vaccine.

The study, published in PLOS Medicine, analyzed data from over 2.2 million vaccine recipients between February and September 2021, representing one of the largest head-to-head comparisons of these vaccine platforms. Researchers found cumulative incidence rates of adverse events of special interest (AESIs) ranging from 0.06% to 0.09% for both vaccines, with all-cause mortality rates remaining very low.

Key Safety Findings

The analysis revealed generally comparable safety profiles between the two vaccines after adjusting for baseline patient characteristics. However, several notable differences emerged for first-dose recipients. CoronaVacView drug details recipients showed a significantly higher incidence rate of Bell's palsy (search)Search disease compared to BNT162b2View drug details recipients, while BNT162b2 recipients experienced higher rates of anaphylaxis (search)Search disease and sleeping disturbances or disorders.

"Despite the slightly higher crude incidence rates of overall AESIs among CoronaVacView drug details recipients than among BNT162b2View drug details recipients, the incidence rates of overall AESIs and all-cause mortality were comparable between the 2 vaccines after weighting," the researchers noted.

Importantly, these significant associations did not persist during the follow-up period after second-dose vaccination, suggesting the differences were primarily related to initial immune responses.

Anaphylaxis and Allergic Reactions

The study confirmed previous observations regarding anaphylaxis (search)Search disease rates. BNT162b2View drug details vaccination was associated with higher rates of anaphylaxis, ranging from 4.7 to 13.7 per million doses in previous studies, compared to an estimated rate of 2.2 per million doses for CoronaVacView drug details. The researchers attributed this difference to potential allergens in each vaccine platform - polyethylene glycol (PEG) excipient in BNT162b2 versus inactivated virus fragments and aluminum hydroxide adjuvant in CoronaVac.

Neurological Events

Bell's palsy (search)Search disease emerged as a significant finding, with CoronaVacView drug details recipients showing higher incidence rates, particularly after the first dose. The researchers noted that "autoimmunity might play a role in the development of Bell palsy, hence calling for an investigation into the immunomodulatory effects of viral antigens and adjuvants of different vaccine platforms."

The study was unable to perform statistical analysis for other neurological conditions like Guillain-Barré syndrome (search)Search disease and transverse myelitis (search)Search disease due to very few recorded cases, which the researchers noted as reassuring given the rarity of these serious conditions.

Cardiovascular Safety Profile

While the study recorded higher crude incidence rates of carditis among BNT162b2View drug details recipients, particularly after the second dose, the small number of cases prevented detailed statistical analysis. The researchers attributed this partly to their exclusion of individuals under 18 years old, as significantly increased risks of acute myocarditis (search)Search disease or pericarditis (search)Search disease have been identified among male adolescents following BNT162b2 vaccination in local studies.

For other cardiac events including arrhythmia, coronary artery disease, and myocardial infarction, no significant differences were identified between the two vaccine platforms.

Thrombotic Events

The analysis found no statistically significant differences in thrombotic and hemorrhagic events between CoronaVacView drug details and BNT162b2View drug details recipients. This finding contrasts with adenoviral vector vaccines, which have been associated with rare thrombotic events. The researchers noted that "BNT162b2 vaccination does not seem to favor these outcomes, nor does the inactivated vaccine CoronaVac."

Study Strengths and Limitations

The research leveraged Hong Kong's unique position as one of the few regions offering both vaccine platforms simultaneously, allowing for direct comparison. The large sample size and population-based design provided substantial statistical power to detect rare adverse events.

However, the researchers acknowledged several limitations, including potential residual confounding despite propensity score weighting, possible underreporting of events managed in private healthcare settings, and insufficient power to draw definitive conclusions about very rare adverse events.

Global Implications

The findings have particular relevance for low- and middle-income countries where inactivated COVID-19 (search)Search disease vaccines like CoronaVacView drug details are predominantly used. The study provides reassurance about the safety profile of inactivated vaccines compared to the extensively studied mRNA platforms.

The researchers emphasized the importance of continued pharmacovigilance, stating that "clinical data and observational reports of COVID-19 (search)Search disease vaccines should continue to be made publicly available for all vaccine platforms in a timely manner, as a means of facilitating the continuous monitoring of vaccine safety."

This comprehensive safety comparison reinforces that both vaccine platforms maintain excellent safety profiles, with the benefits of vaccination clearly outweighing the risks of rare adverse events. The study's findings support continued confidence in both vaccine technologies while highlighting the need for ongoing safety monitoring as vaccination programs evolve globally.